Trial Information

Summary: FIBROMYALGIA STUDY

This is a multicenter, randomized, double-blind, placebo controlled research study with duration lasting up to 36 weeks.

Qualified participants will receive 1 of 4 doses of an investigational medication or placebo for up to 27 weeks.

Subjects who complete 27 weeks will be offered an opportunity to participate in a 6-month open label extension study if they qualify.

Eligibility Criteria: (not inclusive of all criteria)

• Age 18 or older
• Diagnosed with Fibromyalgia Syndrome (FMS)
• Experiencing pain related to the Fibromyalgia

For more information, please contact our office.

If you would like to learn more about participating in this study, please send an e-mail message using the form below.